PressJanuary 19, 2024 Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
PressJanuary 18, 2024 Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences
PressJanuary 18, 2024 Clearmind Medicine Inc. Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement
PressJanuary 17, 2024 Filament Health Completes the First Export of Botanical Psilocybin to Australia
PressJanuary 17, 2024 Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
PressJanuary 17, 2024 MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
LifestyleJanuary 16, 2024 Webinar: Healing October 7th – Using MDMA for PTSD in Israel (Presented by MAPS Israel)
PressJanuary 16, 2024 Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
PressJanuary 16, 2024 Red Light Holland Receives Building Permit for AEM Farms 80,000 Square Foot Mushroom Farm, Adding Substantial Future Production Capacity
PressJanuary 11, 2024 PSYC’s CEO Provides Detailed Update on the State of the Company in Newly Released Podcast Recording
PressJanuary 11, 2024 Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
PressJanuary 11, 2024 Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
PressJanuary 11, 2024 Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
PressJanuary 11, 2024 BRAINWeek 2024 to Feature Three Nationally-Acclaimed, Energizing Keynote Speakers Who Will Address the Field’s Most Relevant Topics on Brain Health.
Market ResearchJanuary 10, 2024 aNUma: Pioneering Psychological Wellbeing Technology for Serious Disease Care and Beyond
PressJanuary 5, 2024 MAPS Public Benefit Corporation Announces Oversubscribed Series A Financing and Renames to Lykos Therapeutics
Psychedelic NewsJanuary 4, 2024 Allegations of Sexual Abuse in the Psychedelic Industry: How to Address and Prevent Misconduct
PressJanuary 4, 2024 Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
